Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

UNBELIEVABLE: Looking into aligos therapeutics s return on capital employed - The Untold Story

Aligos Therapeutics (NASDAQ:ALGS) brought in sales totaling $367.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 13.86%, resulting in a loss of $37.71 million. In Q3, Aligos Therapeutics brought in $1.54 million in sales but lost $33.12 million in earnings.

What Is Return On Capital Employed?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.